Abstract: The present invention relates to a method for preparing solid microcapsules comprising the following steps: a) preparation of a composition C1, which is either a composition C1a, comprising a single hydrophobic solid particle, or a composition C1b comprising a plurality of hydrophobic solid particles dispersed in a hydrophilic phase, b) addition under stirring of the composition C1 in a polymeric composition C2 at a temperature Tb, whereby an emulsion (E1) is obtained; c) addition, under stirring, of the emulsion (E1) in a composition C3 at a temperature Tc, whereby a double emulsion (E2) is obtained; d) applying a shear to the emulsion (E2), whereby a double emulsion (E3) is obtained; and e) the polymerization of the composition C2, whereby solid microcapsules dispersed in the composition C3 are obtained.

Abstract: The present subject matter provides a method for delivering a gene editing composition across a plasma membrane of a cell. Related apparatus, system, techniques, compositions, and articles are also described.

Abstract: A biodegradable adhesive, comprising: % (Parts) Water: 30.43? Defoamer: ?.67 Gelatin: 13.50? Preservative: ?.40 Glycerin, sorbitol, and/or sorbitol solutions and/or a mixture of glycerin, sorbitol and/or sorbitol solutions: 12.00? NaCl: 2.00 Sugar: 41.00? Vanilla Extract: ?.27 Total Parts: 100.00%.

Abstract: The present disclosure utilises 3D printing technology, particularly fused filament fabrication, FFF, 3D printing, in conjunction with solid and/or liquid dispensers to produce solid dosage forms, such as pharmaceutical capsules. Such solid dosage forms have a shell, which is 3D printed, and a core, which is dispensed.

Abstract: A compound barb medical device is provided which includes an elongated body having at least one barb formed along the length of the body, the barb defining an inner surface with a first portion disposed at a first orientation relative to a longitudinal axis of the elongated body, and a second portion disposed at a second orientation relative to the longitudinal axis. Optionally, the barb defines a third portion disposed at a third orientation relative to the longitudinal axis. A method for forming a compound barb on a medical device is also provided.

Abstract: Provided herein is a nanoscale material assembly made up of a plurality of nanoscale structures with a crosslinked polymer thermally deposited on the structures. Also disclosed are methods for preparing the nanoscale material assembly with a deposited crosslinked polymer. Further disclosed are various conditions and materials that when used in the preparation of the nanoscale material assemblies further enhance their mechanical properties. In some embodiments, the nanoscale material assemblies can be either nanoscale yarn assemblies or nanoscale sheet assemblies.

Abstract: Disclosed herein are methods for preventing biofilm formation on a surface. The present disclosure also relates to anti-biofilm forming agents, to methods of producing and using them, and to anti-fouling coatings produced therefrom.

Abstract: A stabilized composition of fat soluble nutrient(s) includes a water soluble polymer and at least one nutraceutically acceptable excipient. The composition can be in the form of significantly amorphous aqueous microparticulate mixtures or as a solid beadlet product. A process for preparation of a stabilized composition includes a fat soluble nutrient solubilized in an organic solvent embedded in an aqueous polymer phase by evaporation, so as to obtain an aqueous microparticulate mixture. This mixture is stable, soluble and can be formulated for end use or can be layered on inert core for example to obtain stable beadlet(s) for use in solid dosage forms. Such stabilized aqueous microparticulate and solid beadlet compositions exhibit good solubility and dispersibility. Stabilized compositions of fat soluble nutrients can be prepared using industrially convenient equipment and can be formulated as per requirement for use in health applications.

Abstract: Disclosed are polymer-coated surfaces encapsulating task specific ionic liquids (ILs), IL complexes, or oils. Also disclosed are polymer-coated surfaces, wherein the polymer comprises ILs or neutral ethylene diamine compounds. Also disclosed are methods of antimicrobial treatment, metal remediation, and gas absorption using polymer coatings encapsulating ILs, IL complexes, and oils or polymer coatings comprising ILs and neutral ethylene diamine compounds.

Abstract: This invention provides a budesonide/formoterol dry powder inhaler (10) comprising: a reservoir (14) containing a dry powder medicament and an arrangement for delivering a metered dose of the medicament from the reservoir; a cyclone deagglomerator (10?) for breaking up agglomerates of the dry powder medicament; a delivery passageway (34) for directing an inhalation-induced air flow through a mouthpiece (24), the delivery passageway extending to the metered dose of medicament, wherein the medicament comprises micronised formoterol fumarate, micronised budesonide and a lactose carrier, the lactose carrier having a particle size distribution of d10=20-65 ?m, d50=80-120 ?m, d90=130-180 ?m and <10 um=<10%.

Abstract: A coated confectionery is provided including a confectionery core and a shell surrounding said confectionery core. The shell includes a soft coating including at least one layer of a first coating material and a hard coating including at least one layer of a second coating material. The soft coating forms at least 25% of a total weight of said shell.

Abstract: Disclosed is a method for the fabrication of polymeric topcoat via initiated chemical vapor deposition (iCVD) or photoinitiated chemical vapor deposition (piCVD) in conjunction with directed self-assembly (DSA) of block copolymers to generate high resolution patterns. A topcoat deposited by iCVD or piCVD allows for conformal, ultra-thin, uniform, pinhole-free coatings. iCVD or piCVD topcoat enables the use of a diversity of block copolymer (BCP) materials for DSA and facilitates the direct and seamless integration of the topcoats for a pattern transfer process.

Abstract: In an apparatus and method of manufacturing a multi-column multi-medicine oral dissolving film according to the present invention, all processes from film feeding, medicine coating, and medicine drying to product packaging are implemented as continuous automation processes, and under the automation processes, different kinds of medicines are coated on a base film in multiple columns in a signal layer by using a plurality of nozzles supplied with the different kinds of medicines, so that it is possible to improve productivity through the automation processes, to ensure product quality due to efficiency during drying caused by maintaining the thickness of the product, and to provide a convenience in the case of taking various kinds of small-amount medicines at one time or in the case of separately and selectively taking different kinds of medicines.

Abstract: A method of making a capsule comprising a plurality of compartments, the method comprising: initiating extrusion of a filament solution through a filament extruder; laying the filament solution to form a base of the capsule; forming a first compartment in the plurality of compartments, wherein the forming creates a first barrier wall having a first predetermined release time; forming a second compartment in the plurality of compartments, wherein the forming creates a second barrier wall having a second predetermined release time; filling the first compartment with a first material; filling the second compartment with a second material; and sealing the plurality of compartments thereby forming the capsule with a first sealed compartment and a second sealed compartment.

Abstract: An antibiotic-eluting article for implantation into a mammalian subject, produced by an additive manufacturing process wherein a polymeric material is concurrently deposited with a selected antibiotic. The additive manufacturing process may be a selective laser sintering process or a selective laser melting process or a selective heat sintering process or an electron beam melting process. The antibiotic-eluting article may be temporary or permanent orthopedic skeletal component, an orthopedic articulating joint replacement component, and/or an external hard-shell casing for an implantable device. One or more bone-growth-promoting compositions may be concurrently deposited with the polymeric material. The implantable device may be a cardiac pacemaker, a spinal cord stimulator, a neurostimulation system, an intrathecal drug pump for delivery of medicants into the spinal fluid, and infusion pump for delivery of chemotherapeutics and/or anti-spasmodics, an insulin pump, an osmotic pump, and a heparin pump.

Abstract: A nanoparticle coated hydrogel may be formed by a method of electrospraying nanoparticles on to a surface includes providing a drug and polymer combination in solvent to an inner capillary of a coaxial dual capillary spray nozzle. A coating with a drug that releases over time may be provided. Open and closed matrixes may be selectively formed to help modify time release periods.

Abstract: A powdered filler composed of solid particles of a cured thermosetting composition comprising a resin modifier such as fumed silica, methods of preparing the cured solid particles, compositions comprising the powdered filler, and articles made from the compositions are disclosed. In embodiments, the solid particles are spherical shaped, transparent or translucent, and have a mean particle size of less than 20 ?m.

Abstract: A process for the preparation of composite filler particles, comprising: (a) coating a particulate filler having a median particle size (D50) of from 1 to 1200 nm; (b) agglomerating the coated particulate filler, for providing a granulation of the coated particulate filler wherein the granulation contains the coated particulate filler particles whereby the at least one coating layer may be crosslinked by crosslinking groups obtained by reacting the reactive groups and optionally a further crosslinking agent.

Abstract: A solid dispersion comprising at least one active ingredient in at least one hydroxyalkyl methylcellulose having a DS of from 1.0 to 2.7 and an MS of from 0.40 to 1.30, wherein DS is the degree of substitution of methoxyl groups and MS is the molar substitution of hydroxyalkoxyl groups, can be produced by extrusion or spray-drying.

Abstract: A fragrance releasing complex with extended fragrance retention capability including an acrylic polymer, to be applied a human body surface is provided. The fragrance releasing complex can be applied by using a kit which includes means for applying the fragrance releasing complex to the body surface.

Abstract: The invention relates to improved isomalt-containing tablets and to methods for the production thereof.

Abstract: The preparation method of radiation-sensitive copolymer carrier for coating radiated nanoparticles and/or chemotherapy drugs includes forming a nanosphere by diselenide block copolymers and DSPE-PEG-biomarkers to coat chemotherapy drugs and/or radiated nanoparticles that can be released from the opened nanosphere by protons penetrating tissue during proton therapy. The treatment effect of proton therapy is enhanced by two ways of using the radiated nanoparticles released from an opened nanosphere to produce nuclear fission with the protons for releasing electrons to destroy cancer cells of tumor and the chemotherapy drugs released from the opened nanosphere for distributing among tissue to kill the cancer cells of the tumor.

Abstract: A method for making a carbon nanotube composite structure includes suspending a carbon nanotube layer in a reactor. A polymer monomer solution and an oxidant solution are gasified by a pressure to form polymer monomer solution gas and oxidant solution gas. The polymer monomer solution gas is polymerized and chemically bonded to the carbon nanotube layer in initiation of the oxidant solution gas.

Abstract: The present disclosure provides systems and methods for actively releasing food additives to deliver aromatic compounds to consumers during food or drink consumption. The food additives may be contained within an encapsulation layer. The encapsulation layer may be configured to release the food additives in response to being exposed to energy provided by an activation source proximate to the food additives. The activation source may be incorporated into, or connected with, an eating utensil or an oral implant. The activation source can be manually controlled by a consumer, can be controlled based on conditions near the food additives, or can be programmed with a release schedule that defines how and when food additives are to be released.

Abstract: The present invention relates to systems for and corresponding methods of delivering a therapeutic agent to a vessel wall of a body lumen by providing a compound capable of being crosslinked after intraluminal release onto a vessel wall so that the therapeutic agent is temporarily retained at the site of delivery by the crosslinked compound.

Abstract: The present invention provides an implantable device having a coating including a slow dissolving polymer or material and the methods of making and using the same.

Abstract: Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.

Abstract: The invention relates to a process for the preparation of tablets containing moxifloxacin, comprising the steps of (i) providing moxifloxacin, pharmaceutically acceptable salts, solvates or hydrates thereof, optionally mixed with one or more pharmaceutical excipients; (ii) compacting it into a slug; (iii) granulating the slug; and (iv) compressing the resulting granules into tablets; and also tablets, granules and compacted material containing compacted moxifloxacin.

Abstract: The present disclosure relates to the field of polymer coating. The present disclosure provides improved systems and methods for continuous polymer coating of particles (e.g., nanoparticles). The present disclosure provides for a solid hollow fiber cooling crystallization (SHFCC) technique to continuously coat the nanoparticles with polymer. In certain embodiments, the present disclosure embraces continuous coating of particles from about 1 nm to about 10 microns. A polymer solution containing a suspension of submicron particles flows in the lumen of a solid polymeric hollow fiber, and controlled cooling of the polymer solution allows for polymer nucleation on the surface of the particles, and the precipitated polymer forms a thin film around the particles (the thickness of which can be varied depending on the operating conditions). The systems, methods and assemblies of the present disclosure are easily adaptable for coating nano-sized drug particles as well.

Abstract: A stable composition with a benzimidazole derivative, such as Omeprazole, which does not contain a separating layer between the active compound and an enteric coating layer. Instead, the enteric coating layer is applied as a solution with a pH value of at least 6.5, and more preferably in a range of from about 7 to about 10, directly to the benzimidazole derivative substrate. This solution, with the optional addition of a plasticizer, can be directly coated onto the substrate without any necessity for an intermediate layer. Furthermore, in this pH range, the enteric coating is optionally applicable in an aqueous solution, thereby obviating the need for organic solvents for dissolving the enteric coating material. The resultant formulation maintains the stability of the benzimidazole derivative during storage and at the same time protects the product during passage through the acidic environment of the stomach.

Abstract: Described herein are pharmaceutical compositions for the delivery of poorly soluble active pharmaceutical ingredients. In particular, a substantially clear fexofenadine HCl solution in a soft gelatin capsule is described.

Abstract: A mixed dose of a nanosized drug wherein at least one portion of the mixed dose comprises a core nanosized drug encapsulated in at least one layer of a protective material having the same core drug or different core drug. A mixed dose of a nanosized drug wherein at least one portion of the mixed dose comprises a core nanosized drug encapsulated in at least one shell of a protective material with same drug concentration or different drug concentrations. A mixed dose of a nanosized drug wherein at least one portion of the mixed dose comprises a core nanosized drug encapsulated such that it has different release schedule than other portions of the drug. Methods and systems for manufacturing and administration of nanosized encapsulated drugs are also provided.

Abstract: A bone implantable medical device made from a biocompatible material, preferably comprising titania or zirconia, has at least a portion of its surface modified to facilitate improved integration with bone. The implantable device may incorporate a surface infused with osteoinductive agent and/or may incorporate holes loaded with a therapeutic agent. The infused surface and/or the holes may be patterned to determine the distribution of and amount of osteoinductive agent and/or therapeutic agent incorporated. The rate of release or elution profile of the therapeutic agent may be controlled. Methods for producing such a bone implantable medical device are also disclosed and employ the use of ion beam irradiation, preferably gas cluster ion beam irradiation for improving bone integration.

Abstract: An implantable medical device is disclosed. The medical device includes a substrate and a polymer composition including ascorbic acid, the polymer composition disposed on at least a portion of the substrate.

Abstract: The present invention relates to methods and apparatus to provide coated microbubbles, particularly but not exclusively microbubbles at least partially coated with a component, for example a clinically active component. Systems of the present invention use electromagnetic fields to move microbubbles between streams of liquids in order to perform coating or washing steps.

Abstract: A process for producing a compressed solid dosage form containing an active ingredient. The process includes a step of preparing core elements containing the active ingredient. Optionally the core elements are coated with a pharmaceutically acceptable coating layer to form coated pellets. The core elements or pellets are treated with an anti-static agent and compressed with suitable excipients to form the compressed solid dosage form. Particular anti-static agents are starch, microcrystalline cellulose, kaolin, bentonite, silicates, silicon dioxide, cellulose, stearic acid, sodium stearyl fumarate and glyceryl behenate.

Abstract: The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the indole hormone melatonin, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition.

Abstract: A taste masked particulate pharmaceutical formulation include a core that comprises an active pharmaceutical ingredient; at least a partial nanoparticle material layer on the core that comprises a nanoparticle material with a median particle size not greater than 100 nm; a first polymer layer that is at least partially water soluble and a second polymer layer that is water insoluble. The active pharmaceutical ingredient is completely released in 30 minutes in the USP Dissolution Test. A process of making the particulate pharmaceutical formulation using sequential fluidized bed coating steps under controlled conditions is also described.

Abstract: The present invention relates to ceria nanocomposite, pharmaceutical composition comprising the ceria nanocomposite, and method for preparing same. More particularly, the present invention is directed to a ceria nanocomposite comprising a ceria nanoparticle, wherein the ceria nanoparticle is encapsulated with a surfactant and the surfactant is encapsulated with polyethylene glycol-phospholipid, pharmaceutical composition for preventing or treating ischemic stroke comprising thereof and method for preparing the same.

Abstract: The present invention provides a method and apparatus for positioning the core of the compression coated tablet in manufacturing techniques for the production of such tablets.

Abstract: Carrier particles in which at least 60% of the surface is coated with magnesium stearate are useful for preparing dry powder formulations for inhalation.

Abstract: A method is disclosed for making a pharmaceutical composition for pulmonary administration, the method comprising a step in which an inhalable pharmaceutically active material is acoustically blended in a resonant acoustic blender. The invention also relates to compositions for inhalation prepared by the method.

Abstract: A method for attaching an implant to tissue is disclosed. In embodiments, a method includes applying a sprayable material to tissue, the sprayable material possessing functional groups capable of binding to tissue. The sprayable material also possesses functional groups capable of binding to an implant. In embodiments, the functional groups capable of binding to an implant include nucleotides. In such a case, the implant possesses complementary nucleotides capable of binding to the nucleotides on the sprayable material, thereby permitting hydrogen binding between the two. The implant may thus be affixed to tissue, and repositioned as necessary, prior to more permanent attachment utilizing means such as sutures, tacks, etc.

Abstract: A cell carrying microsphere composition, wherein the microsphere composition comprises a microspheric core comprising a triblock copolymer matrix A-B-A wherein A is selected from poly(lactide-co-glycolide) (PLGA) or polylactide (PLA) and B is poloxamer or poloxamine, wherein the microspheric core is coated with a cell adhesion coating and further comprises whole cells or cell fragments bonded to the cell adhesion coating, a process for the preparation of a cell carrying microsphere composition, and applications thereof.

Abstract: The various embodiments herein provide super paramagnetic iron oxide nanoparticles (SPIONs). The SPIONs have a plurality of metallic coatings and plurality of polymeric gaps. The embodiments herein also provide a method of synthesizing the SPIONs with metallic rings and polymeric gaps. The metallic coatings form a ring like structure on the outer surface of the SPION. The SPION has a size of 13 nm. The ring has a thickness of 2-3 nm. The rings are one or more in number. The polymeric gaps have a thickness of 3-5 nm. The polymeric gaps are one or more in number. The method involves mixing the SPIONs with a plurality of polymers and then forming a metallic ring on the outer surface of the SPIONs. The SPIONs have anti-bacterial properties and stop a growth of bacterial biofilms. The SPIONs also have SERS properties.

Abstract: A method of method of coating powdered medical agent onto a carrier particle for use in a dry powder inhaler may include applying ultrasonic energy to agglomerated powdered medical agent to deaggregate and aerosolize particles of the medical agent into particles having a desired average particle size, and coating at least one carrier particle with a desired amount of the deaggregated and aerosolized particles of the medical agent.

Abstract: Described is a process for producing pulverulent, antioxidant-comprising coating compositions, comprising providing an aqueous polymer dispersions comprising one or more antioxidants and a polymer obtained by radical polymerization of a) N,N-diethylaminoethyl methacrylate, and b) at least one radically polymerizable compound selected from esters of ?,?-ethylenically unsaturated mono- and dicarboxylic acids with C1-C8-alkanols, wherein the antioxidants are incorporated into the aqueous polymer dispersion in the form of a solution or of a dispersion, and spray processing the aqueous polymer dispersion to provide a powder form.

Abstract: A powder for use in a dry powder inhaler comprises: i) a fraction of fine particle size constituted by a mixture of physiologically acceptable excipient and an additive; ii) a fraction of coarse particles; and iii) at least one active ingredient. The powder is suitable for efficacious delivery of active ingredients into the low respiratory tract of patients suffering from pulmonary diseases such as asthma. In particular, the invention provides a formulation to be administered as dry powder for inhalation which is freely flowable, can be produced in a simple way, is physically and chemically stable and capable of delivering accurate doses and/or high fine particle fraction of low strength active ingredients by using a high- or medium resistance device.

Abstract: The invention is associated with ingestible film coated solid dosage forms comprising natural honey in the coating applied to such forms. The natural honey of the film coated solid dosage form is of sufficient level to be perceived by the user while avoiding sticking to each other or the packaging with which they are in contact and, or storage.

Abstract: Method for providing a biocompatible bone implant adapted to fill a bone cavity or lacuna including the steps of providing granular elements in form of granules and/or granule aggregates, providing at least one primary polymeric solution including a biopolymer, at least partly coating the granular elements with the primary polymeric solution, obtaining coated granular elements including a biopolymer coating, providing a cross-linking solution, dipping the coated granular elements in the cross-linking solution, waiting a period of time referred to as “jellification time” of between 30 seconds and 1 hour, in which during said waiting step there occurs the cross-linking of the biopolymer coating of the granular elements with the cross-linking solution and the jellification of the coating, with the aim of obtaining a cohesive biocompatible implant including granular elements and a bio-reabsorbable biopolymer gel; biocompatible bone implant obtained through such method.